Calvin has led our Finance team since June 2017. Calvin joined Alector from biotechnology company Stemcentrx, Inc. (acquired by AbbVie), where he served as Corporate Controller from February 2016 to June 2017. Prior to Stemcentrx, Calvin held several senior level finance role at publicly traded biotechnology companies, including Senior Director of Finance and SEC Reporting at Adverum Biotechnologies, Inc. from September 2014 to February 2016, and Controller at Five Prime Therapeutics, Inc. from March 2010 to September 2014. Calvin holds a B.S. in Accounting from San Francisco State University, College of Business.